Mode
Text Size
Log in / Sign up
N/A N=72 Diagnostic

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

Glaucoma, Open-Angle

Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Jun 2022
Primary outcome: Primary: Mean Retinal Sensitivity From Two Machines — 29.9; 24.8; 28.7; 22.9 decibels

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer (Diagnostic_test); visuALL Field Analyzer (Diagnostic_test)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Wills Eye
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Retinal Sensitivity From Two Machines
29.9; 24.8; 28.7; 22.9; 30.3; 24.8
PRIMARY
Global Correlation (Agreement Between Two Machines in the Overall Visual Field)
0.5; 0.8
SECONDARY
Inferior Nasal Quadrant Correlation (Agreement Between Two Machines in the Inferior Nasal Visual Field)
0.3; 0.8
SECONDARY
Superior Hemifield Correlation (Agreement Between Two Machines in the Superior Hemifield Visual Field
0.4; 0.6

Summary

To determine age-adjusted reference values of the visuALL Field Analyzer (vFA) retinal sensitivity and to assess the repeatability of the measured values and compare them with those measured by a Standard Automatic Perimetry (SAP).

Eligibility Criteria

Inclusion Criteria

  • age 21 to 80 years
  • Healthy subjects with no eye diseases, normal appearing optic nerve and retina, intraocular pressure less than 19 millimeters mercury and normal standard automatic perimetry (SAP).
  • mild glaucoma subjects with less than -6 mean deviation
  • moderate glaucoma subjects with -6 to -12 mean deviation

Exclusion Criteria

  • spherical refraction outside ± 3.0 diopters and cylinder correction outside 2.0 diopters
  • Unreliable SAP (false positives, fixation losses and false negatives greater than 25% and/or observable testing artifacts)
  • Unreliable visuALL Field Analyzer (vFA) (greater than 25% false positive, excessive fixation losses)
  • SAP abnormality with pattern loss consistent with neurologic and/or other ocular diseases than glaucoma
  • Intraocular surgery in study eye (except non-complicated cataract or refractive surgery performed more than 6 months before enrollment and without posterior capsule opacification)
  • History of systemic condition known to affect visual function
  • History of medication known to affect visual function
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03804684). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search